BRAF N486_P490del

CI-VAR-00002908Explore in graph →CIViC 2794

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Pancreatic Neoplasm1
BRAF N486_P490del	Trametinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID7730 In a case report, a patient with pancreatic cancer harboring BRAF N486-P490del was treated with trametinib. Within 4 weeks of initiating therapy, her serum CA19-9 had fallen from 36,000 to 8,100 U/mL,… (full text at CIViC) PMID 29903880 · Aguirre et al., 2018 · Open in CIViC	civic
Solid Neoplasm2
BRAF N486_P490del	Mitogen-Activated Protein Kinase Kinase Inhibitor	Predictive	D	Supports Sensitivity Response	3	submitted	EID7562 BRAF β3-αC deletions (BRAF N486_P490del, del T488_P492del, or P490_Q494del) are kinase-activating alterations, independent of CRAF and dimerization. Theses BRAF deletions are activating through restr…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Unmapped disease1unmapped disease
BRAF N486_P490del	(functional)	Functional	D	Supports Gain Of Function	3	submitted	EID7563 BRAF β3-αC deletions (BRAF N486_P490del, del T488_P492del, or P490_Q494del) are kinase-activating alterations, independent of CRAF and dimerization. Theses BRAF deletions are activating through restr… (full text at CIViC) PMID 26996308 · Foster et al., 2016 · Open in CIViC	civic